Sign up for our complimentary
weekly e-journal

Main Newsletter
Mastery Series
Therapy Series
Letter From The Editor

DPP4-Inhibitors have been on the market for seven years and, in that time, over 1 million patients have used the drug. Out of those patients, 33 reported severe joint pain. Now the FDA has published a warning, which will possibly cause prescribers and patients to discontinue using the drug. Although calling attention to this may be important, one has to wonder -- if we simply took a million random people, how many of them would have severe joint pain?

We are starting to see an increase in the use of genomic testing for medication selection and now there even seems to be a way to test genomes to see if a pre-diabetes patient will develop diabetes. Check out item 8 to see how it all works.



Announcements: Sunday, September 6, 7PM ET

From "Minding your manners over diabetes — how to teach your friends and family boundaries that keep everyone happy. Then, Chef Michel Nischan serves up a diabetes-friendly Italian classic, and dLife visits "Hardball's" Chris Matthews." Sundays live online at at 7 PM ET, 6 PM CT, and 4 PM PT. Keep up on the latest dLife news at


We can make a difference!


Dave Joffe, Editor-in-chief

 … Read More

Scroll down for items in the current newsletter

Tool for your Practice

altThis list comes from our partner site, (Institute for Safe Medicine Practice). The abbreviations, symbols, and dose designations found in this table have been reported to ISMP through the ISMP National Medication Errors Reporting Program as being frequently misinterpreted and involved in harmful medication errors. List of Abbreviations (PDF)

Product of the Week

altBoehringer Ingelheim and Eli Lilly announced that the Food and Drug Administration (FDA) has approved Synjardy (empagliflozin, metformin HCl) as adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes who are not adequately controlled on a regimen containing empagliflozin or metformin, or in patients already being treated with both empagliflozin and metformin. See Item #1


Mobile App of the Week 



Find & order healthy restaurant meals for delivery, takeout or browse for healthy dish suggestions when you're dining out. More information.








Test Your Knowledge Question #797

Your 42-year old, overweight patient was diagnosed with type 2 diabetes (A1C 7.7%) five months ago. You discussed the diagnosis with him, prescribed metformin and provided lifestyle modification education resources. He missed his follow-up appointment, so you called him to schedule a return visit. At this appointment, he shares some of the positive lifestyle modifications he has made and that he has been taking his metformin consistently. He currently takes 2000 mg metformin per day. At this visit his A1C is 9.4%. All of the following are reasonable treatment options EXCEPT:

A. Metformin+ lifestyle modifications
B. Metformin + once-daily evening basal insulin dose + lifestyle modifications
C. Metformin + sulfonylurea+ lifestyle modifications
D. Metformin + GLP-1 receptor agonist + lifestyle modifications

For the complete question and answer, just follow this link. 

Diabetes In Control Has Over 16000 Studies & Articles In Our Archives

Quote of the Week!

"It is not the mountain we conquer but ourselves."
                          ...Sir Edmund Hillary


Diabetes in Control gratefully acknowledges the assistance of the following pharmacy doctoral candidates in the preparation of this week's newsletter: 

Ashley Spies, USF College of Pharmacy
Shatera Peace, FAMU
Thao Luutran, LECOM
L'Shantey Wells, Creighton College of Pharmacy
Diane Jules, USF College of Pharmacy

Cast Your Vote
What percentage of your patients tests their postprandial blood sugars?

CME/CE of the Week
Martha Funnell, RN

Category: Nursing
Credits: 1